Viatris to buy Pacira BioSciences in $1.65B deal
Viatris (VTRS) and Pacira BioSciences (PCRX) said they entered into a definitive agreement under which Viatris will acquire all outstanding shares of Pacira for $36.50 per share in cash, representing an aggregate equity value of $1.65B.
The transaction is expected to close by the end of 2026.
Upon completion of the transaction, Pacira will become a wholly owned subsidiary of Viatris and Pacira's common stock will no longer be listed for trading on the Nasdaq Global Select Market.
"The proposed transaction is expected to be immediately accretive to our financial guidance metrics," said Paul Campbell, Interim CFO, Chief Accounting Officer & Corporate Controller, Viatris. "Importantly, we expect to fund the transaction primarily from excess cash with the remainder from short-term borrowings. As such, we expect the transaction will have minimal impact on our gross leverage ratio.
Recommended For You
Create Your Free Account to Keep Reading
Get the confidence to navigate an uncertain market with free breaking news and stock alerts.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.